Skip to content
OpenCapital
Get started

Theravance Biopharma TBPH Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue$45.9MMiss by $10.7M
EPS$0.06Miss by $0.38
Revenue estimate$56.6M
EPS estimate$0.44

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$22.5M
EPS estimate$0.07

Financials

Q4 2025

Income statement

See full
Revenue$45.9M+145%
Operating income$20.0M+318%
Net income$61.0M+493%
EPS (diluted)$1.15+471%

Balance sheet

See full
Cash & equivalents$167.8M+344%
Total debt$42.7M-14.3%
Total equity$296.7M+69.0%
Total assets$485.6M+37.1%

Cash flow

See full
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$948.08M+105%
Enterprise value$822.98M+73.3%
P/E9×—
P/S8.8×+1.6×

Profitability

See full
Operating margin-3.4%-1.6pp
Net margin98.5%+67.0pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity44.8%+32.2pp
Debt / equity0.1×-0.1×
Current ratio10.9×+5.9×

Segments

By segment

See full
Single Reportable$45.9M+145%

Versus estimates

Revenue

Q1 2026$17.7MMiss by $84.3K
Q4 2025$45.9MMiss by $10.7M
Q3 2025$20.0MMiss by $23.1MQ2 2025$26.2MBeat by $7.5MQ1 2025$15.4MMiss by $712.0KQ4 2024$18.8MBeat by $1.7M

Diluted EPS

Q1 2026-$0.10Miss by $0.12
Q4 2025$0.06Miss by $0.38
Q3 2025$0.04Beat by $0.07Q2 2025-$0.08Beat by $0.06Q1 2025-$0.17Miss by $0.06Q4 2024-$0.05In line

Ask the moment Theravance Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Theravance Biopharma report Q4 2025 earnings?
Theravance Biopharma (TBPH) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Theravance Biopharma's Q4 2025 revenue and EPS?
Theravance Biopharma reported revenue of $45.9M and eps of $0.06 for Q4 2025.
Did Theravance Biopharma beat estimates in Q4 2025?
Revenue missed the consensus estimate of $56.6M by $10.7M. EPS missed the consensus estimate of $0.44 by $0.38.
How did Theravance Biopharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 144.7% from $18.8M a year earlier.
Where can I find Theravance Biopharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-031795) and the 10-K periodic report (0001104659-26-033077) directly on SEC EDGAR. The filing index links above go to sec.gov.